Core Group

Action Participants - Core Group

Prof. Barbara Klajnert-Maculewicz (barbara.klajnert@biol.uni.lodz.pl)

Action chair, GH scientific representative, MC member
Working Groups 1 and 2
Department of General Biophysics
University of Lodz
Lodz, Poland

https://orcid.org/0000-0003-3459-8947/print

Prof. Barbara Klajnert-Maculewicz's group concentrates on using different nanosystems (especially dendrimers) as drug carriers in cancer therapies. We are studying complexes with photosensitizers used in photodynamic therapy, complexes with nucleotide analogues, and conjugates with anticancer drugs and monoclonal antibody. We possess cell culture laboratory with access to flow cytometer and confocal microscope, and biophysical laboratory equipped with spectrofluorimeters, CD spectrometer, zeta-sizer).


Prof. Carlo V. Catapano (carlo.catapano@ior.usi.ch)

Working Group 3 leader, MC member
Working Groups 3 and 4
Department of Tumor Biology and Experimental Therapeutics
Institute of Oncology Research (IOR) and Università della Svizzera italiana (USI)
Bellinzona, Switzerland

http://www.ior.usi.ch

My group is investigating transcriptional, epigenetic and metabolic processes in human cancers and developing innovative therapeutic strategies based on small-molecules, oligonucleotides and small interfering RNAs. These processes underlie the tumor heterogeneity and phenotypic reprogramming associated with stemness, metastasis, tumor progression and treatment resistance. We have established protocols and in vitro/in vivo experimental models to study these aspects and testing delivery and efficacy of novel therapeutics.


Dr. Ivana Vinković Vrček (ivinkovic@imi.hr)

Working Group 2 leader, MC member
Working Groups 2, 3 and 4
Analytical Toxicology and Mineral Metabolism Unit
Institute for Medical Research and Occupational Health
Zagreb, Croatia

https://www.imi.hr/en/

Dr. Vinković Vrček’s group is focused on nanosafety and risk/benefit ratio assessment of nano-enabled medicines and medical devices. Their research activities cover all aspects of Safe-by-Design approach: from design, synthesis and chemico-physical characterization to in vitro/in vivo evaluation.


Dr. Ling Peng (ling.peng@univ-amu.fr)

Working Group 1 vice-leader, MC member
Working Groups 1, 2, 3 and 4
Centre Interdisciplinaire de Nanoscience de Marseille
Centre National de Recherche Scientifique (CNRS)
Marseille, France

http://www.cinam.univ-mrs.fr/cinam/spip.php?page=perso&name=peng

Dr. Peng’s group is actively working on the design, synthesis and evaluation of functional dendrimer nanosystems for the delivery of drug, gene and imaging agent for cancer diagnosis and treatment. The laboratory activity includes design, synthesis and physico-chemical characterization. Currently available facilities at Dr Peng's lab are access to nanomaterial synthesis and characterization including NMR, MS, HPLC, DLS, TEM etc.


Dr. Maria Eugenia Riveiro (eugenia.riveiro@e2dg.com)

Working Group 4 leader, MC member
Working Groups 3 and 4
Early Drug Development Group, SAS (E2DG)
Paris, France

www.e2dg.com

E2DG is specialized in the early development of novel leads and targets in oncology. In the last 20 years, we worked in the evaluation of over 15 different oncology leads (at least 8 first-in-man), covering both small molecules, monoclonal antibodies or novel technologies as nanomedicines in oncology. Currently, as E2DG’s Chief Scientific Officer, I support our collaborators to optimize and accelerate their R&D programs, from lead optimization to Phase I clinical trials in oncology. In addition, I am specialized in molecular pharmacology assessments, PK/ADME and CMC regulatory compliance and intellectual property rights in biotechnology companies.


Prof. Maria Francesca Ottaviani (maria.ottaviani@uniurb.it)

STSM coordinator, MC member
Working Group 2
Laboratory of Physical Chemistry, Department of Pure and Applied Sciences (DiSPeA)
University of Urbino Carlo Bo'
Urbino, Italy

https://www.uniurb.it/persone/maria-ottaviani

Prof. Ottaviani's group is characterizing new drugs and drug carriers, mainly dendrimers and surfactant aggregates (like micelles, liposomes, and microemulsions) and their interactions with cell lines, mostly cancer lines compared to healthy lines. Physico-chemical characterization of the bio-relevant molecules and their interactions is mainly performed by an in-situ technique, namely the electron paramagnetic resonance (EPR) spectroscopy, by means of selected spin probes and spin labels. A computer aided analysis of the results provided unique and specific structural and dynamical information.


Prof. Rana Sanyal (rana.sanyal@boun.edu.tr)

Working Group 1 leader, MC member
Working Groups 1, 3 and 4
Department of Chemistry, Center for Life Sciences and Technologies
Bogazici University
Bebek/Istanbul, Turkey

http://www.chem.boun.edu.tr/

Prof. Sanyal’s group is synthesizing nanomedicines for targeting cancer. The laboratory activity includes synthesis of polymers and nanoparticles, characterization, in vitro and in vivo studies. A list of currently available facilities at Prof. Sanyal’s lab can be found at https://lifesci.boun.edu.tr/en and https://sanyalgroup.boun.edu.tr/


Prof. Sabrina Pricl (sabrina.pricl@dia.units.it)

Action vice-chair, Action dissemination manager, MC member
Working Groups 1, 2, 3 and 4
Molecular Biology and Nanotechnology Lab (MolBNL@UniTS)
Department of Engineering and Architecture
University of Trieste
Trieste, Italy

http://www.mose.units.it/default.aspx

Prof. Pricl's group is active in the discovery of new cancer nanomedicines from computer-assisted design to their in vitro activity. The MolBNL@UniTS Lab has access to local and natoonal/international supercomputers for the in silico studies, synchrotron radiation facility for structural studies, different spectroscopic, spectrophotometric and other analytica instruments for nanomedicine characterization, including CD-based stopped flow apparatus and isothermal titration calorimetry for kinetic and thermodynamic measurements. Different  naive and durg resistant cell lines are also avaialbe for in vitro efficacy of nanomedicines.


 

 

European Cooperation in Science and Technology (COST) logo
EU flag logo

Funded by the Horizon 2020 Framework Programme
of the European Union